In April 2023, Pfizer Canada announced Health Canada accepted RSVpreF for review for both individuals ages 60 and older and as a maternal immunization to help protect infants against RSV. INDICATION FOR ABRYSVO ABRYSVO is a vaccine indicated for the prevention of lower respiratory tract...
FDA advisers back Pfizer’s maternal RSV vaccine after voicing safety concerns. BMJ 381, 1187 (2023). Article PubMed Google Scholar McLellan, J. S. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr. Opin. Virol. 11, 70–75 (2015). Article CAS PubMed Pub...
Stock Analysis Stock Ideas Long Ideas Stock Upgrades & Downgrades Editors' Picks Quick Picks & Lists Emerging Markets Stock Screener Stocks by Quant Top Stocks Top Quant Dividend Stocks High Dividend Yield Stocks Top Dividend Stocks ETFs & Funds ETF Screener ETF Analysis E...